Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Common Equity (2022 - 2025)

Atara Biotherapeutics' Common Equity history spans 4 years, with the latest figure at -$38.5 million for Q4 2025.

  • For Q4 2025, Common Equity rose 60.42% year-over-year to -$38.5 million; the TTM value through Dec 2025 reached -$38.5 million, up 60.42%, while the annual FY2025 figure was -$38.5 million, 60.42% up from the prior year.
  • Common Equity reached -$38.5 million in Q4 2025 per ATRA's latest filing, down from -$36.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $257.5 million in Q2 2022 to a low of -$110.9 million in Q2 2024.
  • Average Common Equity over 4 years is $22.1 million, with a median of -$35.8 million recorded in 2025.
  • Peak YoY movement for Common Equity: tumbled 1587.36% in 2024, then soared 68.39% in 2025.
  • A 4-year view of Common Equity shows it stood at $126.6 million in 2022, then decreased by 21.64% to $99.2 million in 2023, then plummeted by 198.04% to -$97.3 million in 2024, then skyrocketed by 60.42% to -$38.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Common Equity are -$38.5 million (Q4 2025), -$36.6 million (Q3 2025), and -$35.0 million (Q2 2025).